 A Message From Paradigm Press Below is an important message from one of our highly valued sponsors. Please read it carefully as they have some special information to share with you.
Consider this your notice. Here's what's happening. I believe 1,806,000 Americans are going to be millionaires in the coming years from this. Almost nobody knows about this yet. Elon buried his next move in a government filing and said nothing. I found it and I believe it's his biggest play yet, and I'll show you the whole thing… Why he's hiding it, and what to do before the 25th. >> WATCH THIS BEFORE DECEMBER 8th!! << It’s completely FREE to watch. No purchase. No credit card. The clock's already running. Don't let it run out. Sincerely,
James Altucher
Just For You
AI Chip Demand Gives Linde a New Growth CatalystAuthored by Peter Frank. Publication Date: 10/6/2026. 
Key Points
- Linde's electronics backlog reached a record $8.1 billion, driven by surging semiconductor fab demand tied to the AI buildout.
- Despite record sales and earnings growth, Linde's shares fell about 6% on earnings day after operating margins slipped due to its struggling Lincare home care unit.
- Analysts remain overwhelmingly bullish, with 21 of 23 rating Linde a Buy and a consensus price target implying roughly 13% upside from current levels.
- Special Report: Important X Money PREDICTION
Linde (NASDAQ: LIN) has been selling gases—nitrogen, oxygen, argon and hydrogen—for more than a century, primarily to hospitals, food companies and refineries. Now, however, it is riding the wave of surging semiconductor demand and a record $8.1 billion backlog.
Although industrial gases may not be the first thing many tech-focused investors consider, the technology sector has helped Linde earn an overwhelming Buy recommendation from analysts. The artificial intelligence buildout has made semiconductor fabs one of Linde's fastest-growing markets. Yet the stock has been held back. To understand the strengthening growth story alongside the sagging share price, investors should consider the broader issues facing the company. Record Sales Meet New Margin PressureOn the surface, Linde's July 31 report looked excellent. Sales rose 9.3% to a record $9.29 billion, while underlying sales increased 4%, reflecting 2% higher prices and 2% higher volumes. That topped the $9.02 billion analysts expected. Earnings grew even faster. Diluted earnings per share rose 11.3% to $4.15. Adjusted earnings per share (EPS) climbed 10% to $4.50, narrowly exceeding the $4.49 consensus estimate. Linde also continued to buy back stock and pay dividends, returning $1.59 billion to shareholders during the quarter. The blemish, however, was profitability. Adjusted operating profit rose 7%, but the adjusted operating margin slipped to 29.5%, down 60 basis points from a year earlier. For a company that has built its reputation on expanding margins, that was enough to send the shares down about 6% on earnings day. Lincare Emerges as the Main Margin DragOperationally, the primary culprit was Lincare, Linde's U.S. home care business, which supplies oxygen and respiratory equipment to patients at home. CEO Sanjiv Lamba said cost inflation and policy changes have made it difficult for Linde to streamline the unit. As a result, he raised the possibility of selling the business, telling analysts that the company was evaluating “the strategic fit of this U.S. home care business within Linde, both in part and as a whole.” Still, the core engine kept humming. Electronics sales grew 18% during the quarter, and management raised the low end of its full-year adjusted EPS outlook to $17.70 to $17.90, implying growth of 8% to 9%. AI Chip Demand Is Powering Linde’s BacklogThe heart of the investment thesis is straightforward: Linde's contracted sale-of-gas backlog reached a record $8.1 billion after the company added $1 billion in new electronics work. On the same day as its earnings release, Linde announced it would invest $1 billion to build two new air separation units in Phoenix for one of the world's largest semiconductor manufacturers, supplying gases for two new fabs. Lamba said he expects electronics to remain Linde's largest backlog contributor and one of its fastest-growing markets, with more than 20 projects worth about $1.3 billion set to start up before year-end. Other industrial markets were also improving, with aerospace accounting for more than a third of manufacturing growth during the quarter. Slower Growth Tests Linde’s Premium ValuationThere are reasons for concern, however, and the market has picked up on many of them. Shares are currently trading roughly where they were a year ago. Although up about 14% from the start of this year, they have dropped about 10% over the past three months. Linde's premium valuation is one issue. The company has relied on its ability to expand margins, and that streak is now being questioned. Barely exceeding per-share expectations did not help, particularly as industrial demand outside the U.S. remains sluggish. Margins in Asia also slipped because Linde is selling lower-margin equipment to electronics customers, the company said, though management expects that business to recover in the coming quarters. Management's third-quarter outlook of $4.45 to $4.55 in adjusted earnings per share implies slower growth of 6% to 8%. Linde is scheduled to report third-quarter results on Oct. 29. Beyond the headline earnings figures, investors will be watching for any update on the strategic review of Lincare, whether margin pressure is beginning to ease, and how quickly the company is converting its record sale-of-gas backlog into revenue as new electronics projects come online. The report could help determine whether the recent weakness in the stock is a temporary pause or a sign that growth is beginning to moderate. Perhaps the more important risk, though, is what investors are paying for growth that is steady rather than spectacular. If chipmakers slow their fab buildouts, some of that investment could earn less than planned. Even with these areas of caution, analysts remain firmly in Linde's corner. Twenty-one of the 25 analysts tracking the company rate it a Buy, while two rate it a Strong Buy. Only two analysts rate it a Hold. Overall, the consensus 12-month target price is $546.80 per share, about 13% above current trading levels. The highest price target is $580 per share, while the lowest is $460. The Recent Dip May Offer an OpportunityThese days, Linde finds itself in a somewhat in-between investment state. It is not one of the high-flying growth stocks, nor is it a bargain-bin value stock. It is a high-quality compounder that may have simply hit a pothole. The stock market is treating the Lincare problem as a possible reason to sell, but the bigger story is a record backlog tied to AI chip demand that could drive growth for years. Assuming margins recover and the third-quarter report is healthy, the recent dip in the stock could prove to be a solid opportunity. . |
No comments:
Post a Comment